A key factor in enhancing patient accessibility to effective and safe medications lies in having an encompassing reimbursement process. In a number of countries, regional or national HTA bodies play a vital role in assessing whether the efficacy, safety, and economics of a health technology warrants reimbursement. While the HTA bodies assess the evidence, the onus rests on the manufacturer to research and compile information on the epidemiology, burden of illness, current standard of care and guideline recommendations, efficacy and safety, health economic analyses etc. The sensitivity and importance of HTA assessments cannot be understated; therefore, our expert scientists and methodologists at Evidinno take great care in adherence to the latest industry standards and HTA guidance for conducting the systematic literature reviews and health economic models that are needed for reimbursements. We have prepared numerous systematic literature reviews in support of successful submissions to HTA bodies.